Credit Suisse’s Anavex Life Sciences AVXL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2024
Q1
$502K Buy
98,689
+1,225
+1% +$6.24K ﹤0.01% 2632
2023
Q4
$907K Buy
97,464
+260
+0.3% +$2.42K ﹤0.01% 2390
2023
Q3
$637K Sell
97,204
-17,270
-15% -$113K ﹤0.01% 2548
2023
Q2
$931K Buy
114,474
+25,311
+28% +$206K ﹤0.01% 2412
2023
Q1
$764K Buy
89,163
+4,191
+5% +$35.9K ﹤0.01% 2467
2022
Q4
$787K Buy
84,972
+18,248
+27% +$169K ﹤0.01% 2492
2022
Q3
$689K Buy
66,724
+6,916
+12% +$71.4K ﹤0.01% 2570
2022
Q2
$599K Buy
59,808
+5,899
+11% +$59.1K ﹤0.01% 2714
2022
Q1
$663K Buy
53,909
+9,603
+22% +$118K ﹤0.01% 2798
2021
Q4
$769K Buy
44,306
+657
+2% +$11.4K ﹤0.01% 2762
2021
Q3
$784K Buy
43,649
+3,719
+9% +$66.8K ﹤0.01% 2738
2021
Q2
$913K Buy
+39,930
New +$913K ﹤0.01% 2694
2021
Q1
Sell
-15,071
Closed -$81K 3407
2020
Q4
$81K Buy
+15,071
New +$81K ﹤0.01% 3345
2020
Q2
Sell
-10,900
Closed -$35K 3280
2020
Q1
$35K Buy
+10,900
New +$35K ﹤0.01% 3304
2019
Q2
Sell
-21,902
Closed -$67K 3426
2019
Q1
$67K Sell
21,902
-14,603
-40% -$44.7K ﹤0.01% 3290
2018
Q4
$57K Sell
36,505
-2
-0% -$3 ﹤0.01% 3253
2018
Q3
$100K Sell
36,507
-849
-2% -$2.33K ﹤0.01% 3240
2018
Q2
$98K Sell
37,356
-13,144
-26% -$34.5K ﹤0.01% 3373
2018
Q1
$140K Buy
50,500
+3,308
+7% +$9.17K ﹤0.01% 3329
2017
Q4
$153K Sell
47,192
-14,824
-24% -$48.1K ﹤0.01% 3293
2017
Q3
$257K Buy
62,016
+18,502
+43% +$76.7K ﹤0.01% 3331
2017
Q2
$231K Buy
43,514
+3,022
+7% +$16K ﹤0.01% 3191
2017
Q1
$233K Sell
40,492
-8,512
-17% -$49K ﹤0.01% 3218
2016
Q4
$194K Sell
49,004
-16,933
-26% -$67K ﹤0.01% 3461
2016
Q3
$239K Buy
65,937
+14,660
+29% +$53.1K ﹤0.01% 3408
2016
Q2
$314K Sell
51,277
-51,650
-50% -$316K ﹤0.01% 3374
2016
Q1
$505K Buy
102,927
+5,488
+6% +$26.9K ﹤0.01% 2936
2015
Q4
$543K Buy
+97,439
New +$543K ﹤0.01% 3102